Iodinated contrast agents in myasthenia gravis

Area of Science:

• Neurology
• Radiology

Background:

• Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
• Previous reports suggest intravenous iodinated contrast agents may exacerbate MG symptoms.

Observation:

• A retrospective review of 136 myasthenia gravis patients undergoing procedures with intravenous contrast media was conducted.
• The study assessed the incidence of contrast reactions and worsening of MG symptoms.

Findings:

• The overall contrast reaction rate was 5.1%, similar to the general population (5%).
• Only one patient experienced increased respiratory muscle weakness potentially linked to contrast, while other weakness increases had alternative explanations.
• No definitive link was established between contrast administration and significant MG symptom exacerbation.

Implications:

• Intravenous contrast agents are not absolutely contraindicated in patients with myasthenia gravis.
• Clinicians should exercise increased vigilance when administering contrast media to MG patients.
• Further research may clarify the specific risks and management strategies for MG patients requiring contrast-enhanced imaging.